Huanyu Zhao

ORCID: 0000-0003-4041-5617
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Wnt/β-catenin signaling in development and cancer
  • RNA modifications and cancer
  • Cancer-related gene regulation
  • Epigenetics and DNA Methylation
  • Liver Disease Diagnosis and Treatment
  • Cancer Immunotherapy and Biomarkers
  • Renal cell carcinoma treatment
  • RNA Research and Splicing
  • Hepatocellular Carcinoma Treatment and Prognosis
  • MicroRNA in disease regulation
  • Pancreatic and Hepatic Oncology Research
  • Lung Cancer Research Studies
  • Cancer-related Molecular Pathways
  • Cancer-related molecular mechanisms research
  • Liver physiology and pathology
  • Oral health in cancer treatment
  • Peptidase Inhibition and Analysis
  • Cancer Cells and Metastasis
  • Lymphoma Diagnosis and Treatment
  • Lung Cancer Diagnosis and Treatment
  • CNS Lymphoma Diagnosis and Treatment
  • Bladder and Urothelial Cancer Treatments
  • Ferroptosis and cancer prognosis
  • Biochemical effects in animals
  • Head and Neck Cancer Studies

First Hospital of China Medical University
2017-2025

China Medical University
2016-2025

State Key Laboratory of Medicinal Chemical Biology
2020-2024

Nankai University
2020-2024

Affiliated Eye Hospital of Wenzhou Medical College
2020-2024

Second Military Medical University
2022-2024

Wenzhou Medical University
2020-2024

Huaian First People’s Hospital
2021-2023

Nanjing Medical University
2011-2023

Tumor Hospital of Xinjiang Medical University
2023

•Objective responses and survival were comparable between intent-to-treat (ITT) overall population Asian cohort.•Median in patients was similar across HCC aetiologies.•Nivolumab had a manageable safety profile both the ITT cohort. Background & AimsNivolumab, an immune checkpoint inhibitor, is approved several countries to treat sorafenib-experienced with HCC, based on results from CheckMate 040 study (NCT01658878). Marked differences exist clinical presentation, aetiology, treatment patterns...

10.1016/j.jhep.2019.05.014 article EN cc-by-nc-nd Journal of Hepatology 2019-06-07

Hydrogen peroxide (H2O2)-induced mitochondrial oxidative damage is critical to intestinal ischemia/reperfusion (I/R) injury, and PRDX3 an efficient H2O2 scavenger that protects cells from apoptosis. However, the function of in I/R injury unclear. The aim this study was investigate precise mechanism underlying involvement injury. An model established mice with superior mesenteric artery occlusion, Caco-2 were subjected hypoxia/reoxygenation (H/R) for vivo simulation I/R. expression decreased...

10.1016/j.redox.2019.101343 article EN cc-by Redox Biology 2019-10-12

Background: p66Shc is a redox enzyme that mediates mitochondrial reactive oxygen species (ROS) generation.p66Shc inhibition confers protection against liver injury, however, its functional contribution to fibrosis remains unclear.The aim of this study explore the involvement in and underlying mechanism by focusing on ROS.Methods: p66Shc-silenced mice were injected with carbon tetrachloride (CCl 4 ).Primary hepatic stellate cells (HSCs) performed silencing or overexpression prior TGF-β1...

10.7150/thno.29620 article EN cc-by Theranostics 2019-01-01

Transmembrane protein 88 (TMEM88) is a transmembrane that plays crucial role in regulating human stem cell differentiation and embryonic development. However, its expression clinicopathologic significance neoplasms unclear. In this study, the subcellular localizations of TMEM88 were assessed 214 cases non-small lung cancer (NSCLC). Notably, was highly expressed cytosol ∼60% NSCLC specimens examined. Higher cytosolic correlated significantly with poor differentiation, high TNM stage, lymph...

10.1158/0008-5472.can-14-3828 article EN Cancer Research 2015-09-11

554 Background: Nivolumab (NIVO) provided durable responses (ORR, 32% per central assessment) and disease control (DCR, 64%) in pre-treated pts with dMMR/MSI-H mCRC (NCT02060188; Overman MJ et al Lancet Oncol 2017). NIVO was approved the US for who progress after standard chemotherapy (SC) a fluoropyrimidine (F), oxaliplatin (Ox), irinotecan (Iri). Here we present long-term survival outcomes by prior CheckMate-142. Methods: Pts received 3 mg/kg Q2W. The primary endpoint ORR RECIST 1.1. Other...

10.1200/jco.2018.36.4_suppl.554 article EN Journal of Clinical Oncology 2018-02-01

4507 Background: Nivolumab, a programmed death-1 (PD-1) immune checkpoint inhibitor, was recently approved by the FDA for patients with clear-cell aRCC previously treated anti-angiogenic therapy based on results from phase III CheckMate 025 study, which showed significantly longer median OS nivolumab vs everolimus (25.0 19.6 months; P = 0.002) minimum follow-up of 14 months (Motzer et al, N Engl J Med 2015;373:1803–13). Because early survival benefit seen in there is increased interest...

10.1200/jco.2016.34.15_suppl.4507 article EN Journal of Clinical Oncology 2016-05-20

We report the preparation of novel Pd/CN catalysts, which can efficiently catalyze hydrogenation nitroaromatic compounds to produce primary amines under very mild conditions.

10.1039/d3nj05050e article EN New Journal of Chemistry 2024-01-01

498 Background: Based on assessment by an independent Data Monitoring Committee, a phase III trial of NIVO (n=410) vs EVE (n=411) in previously treated patients with advanced or metastatic RCC (NCT01668784) was halted early as it met its endpoint; superior overall survival (OS) seen EVE. We present outcomes key baseline factors, prior therapy, and subsequent anticancer therapy. Methods: Patients 1 2 anti-angiogenic therapies measurable disease (RECIST v1.1) were randomized 1:1 to 3 mg/kg IV...

10.1200/jco.2016.34.2_suppl.498 article EN Journal of Clinical Oncology 2016-01-10

Fibrosis reflects a progression to liver cancer or cirrhosis of the liver. Recent studies have shown that high-mobility group box-1 (HMGB1) plays major role in hepatic injury and fibrosis. Carnosic acid (CA), compound extracted from rosemary, has been reported alleviate alcoholic nonalcoholic fatty injury. CA can also renal We hypothesized might exert anti-liver fibrosis properties through an HMGB1-related pathway, results present study showed treatment significantly protected against bile...

10.3389/fphar.2017.00976 article EN cc-by Frontiers in Pharmacology 2018-01-19

Yinqiao Antipruritic Formula (YQAF) is a traditional Chinese medicine (TCM) formula for treating atopic dermatitis (AD) that has been used by the Huzhou Traditional Medicine Hospital in long-term clinical practice. It definite therapeutic effects and minimal toxic side effects. However, specific mechanism underlying of YQAF on AD remains ambiguous. We demonstrated effect Th2 type inflammation 2,4-dinitrochlorobenzene (DNCB)-induced mice model elucidated mechanism. Results showed effectively...

10.2139/ssrn.5082891 preprint EN 2025-01-01

Background: Glucose transporter 1 (GLUT1) is the main factor of Warburg effect, which associated with poor prognosis in many tumors.However, underlying molecular mechanism GLUT1 progression non-small cell lung cancer (NSCLC) unclear.Methods: We used quantitative real-time PCR to detect mRNA expression bronchial brushing samples and performed Western Blot biological behavior testing check effect on NSCLC proliferation, migration, invasion apoptosis.Results: found that C(t) normalized value...

10.7150/jca.30772 article EN cc-by-nc Journal of Cancer 2019-01-01

The WNT5B ligand regulates the non-canonical wingless-related integration site (WNT)-planar cell polarity (PCP) pathway. However, detailed mechanism underlying activity of in WNT-PCP pathway non-small lung cancer (NSCLC) is unclear. In this study, we assessed clinicopathological significance expression NSCLC specimens. WNT5B-overexpression and -knockdown lines were generated vivo vitro, respectively. overexpression specimens correlates with advanced tumor node metastasis (TNM) stage, lymph...

10.1016/j.cellsig.2024.111330 article EN cc-by Cellular Signalling 2024-07-31

Disabled-2 (Dab2) is considered a tumor suppressor and downregulated in cancers. We examined the promoter methylation status expression levels of Dab2, investigated their roles development lung Methylation-specific PCR was employed to analyze Dab2 100 cancer tissues. The cytoplasmic nuclear protein determined using western blot analysis. Demethylation treatment 5-Aza-2-deoxycytidine (5-Aza-dC) performed three cell lines. upregulated by transfection or interrupted siRNA cells. Proliferative...

10.3892/ijo.2013.2084 article EN International Journal of Oncology 2013-08-29

The epithelial mesenchymal transition (EMT) is an important process in tumor development. Despite previous investigations, it remains unclear how p120-catenin (p120ctn) isoforms 1A and 3A affect the EMT of cells. Here we investigated expression p120ctn, E-cadherin vimentin 78 human non-small cell lung cancer (NSCLC) samples by immunohistochemistry found that p120ctn membrane positively correlated with (P<0.001) negatively lymph node metastasis (P<0.05). Meanwhile, cytoplasmic Cells...

10.1371/journal.pone.0088064 article EN cc-by PLoS ONE 2014-02-04

Salvianolic acid A (SalA) is a water-soluble phenolic carboxylic extracted from Salvia miltiorrhiza that has extensive pharmacological activities and plays an essential role in liver disease treatment. However, the mechanism of SalA treating alcoholic (ALD) remains unclear. Here, we studied protective effects on chronic ethanol-induced injury involving Sirtuin 1 (SIRT1)-mediated autophagy activation. The results showed pretreatment reduced levels alanine aminotransferase (ALT), aspartate...

10.1039/c8ra00798e article EN cc-by RSC Advances 2018-01-01

IQ-domain GTPase-activating protein 1 (IQGAP1) binds to Dishevelled (Dvl) and functions as a modulator of Dvl nuclear localization in Xenopus embryos. However, the relationship between IQGAP1 tumor tissues is unclear.We used immunohistochemistry assess expressions cohort 111 non-small cell lung cancer (NSCLC) patients. Association their with clinicopathological factors was also analyzed.The positive rate primary tumors 48.6% (54/111) for its cytoplamic expression, 9.0% (10/111) expression...

10.1371/journal.pone.0113713 article EN cc-by PLoS ONE 2014-12-01
Coming Soon ...